Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Apr 27;9(1):255-61.
doi: 10.1159/000445940. eCollection 2016 Jan-Apr.

Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case

Ray Manneh  1 , Daniel Castellano  1 , Oscar Caso  2 , Carmelo Loinaz  2 , Jesús Jiménez  3 , Juana Estenoz  4 , Maria Calatayud  5 , Juan M Sepúlveda  1 , Rocio García-Carbonero  1
Affiliations
Case Reports

Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case

Ray Manneh et al. Case Rep Oncol. .

Abstract

Treatment of metastatic gastric neuroendocrine tumours (NETs) is challenging. In oligometastatic cases, surgical resection is recommended whenever possible. Somatostatin analogues have been used to decrease gastrin levels, and available evidence suggests that these drugs can also reduce recurrences. Here we present a highly unusual case involving a patient with a well-differentiated grade 2, type 3 gastric NET with exclusive metastatic bilateral ovarian involvement. To our knowledge, this is the first such case reported in the literature, as the cause of ovarian involvement is usually due to local invasion rather than metastasis. We believe this case is of interest not only due to the unusual presentation, but also because it makes us consider adjuvant treatment with somatostatin analogues in patients with low-grade tumours and a positive postoperative octreoscan.

Keywords: Gastric cancer; Neoplasm recurrence, local; Neuroendocrine tumors; Somatostatin; Stomach neoplasms.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
18FDG-PET/CT depicting the left ovarian lesion. SUVmax = 4.7.
Fig. 2
Fig. 2
18FDG-PET/CT showing the gastric mass. SUVmax = 11.2.
Fig. 3
Fig. 3
Octreoscan showing the gastric mass (top image) and ovarian lesion (bottom image).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pericleous M, Toumpanakis C, Lumgair H, Caplin ME, Morgan-Rowe L, Clark I, Luong TV. Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature. Case Rep Oncol. 2012;5:313–319. - PMC - PubMed
    1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J-N, Rashid A, Evans DB. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. - PubMed
    1. Strosberg J, Nasir A, Cragun J, Gardner N, Kvols L. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol. 2007;106:65–68. - PubMed
    1. Pavel M, Grossman A, Arnold R, Perren A, Kaltsas G, Steinmüller T, de Herder W, Nikou G, Plöckinger U, Lopes JM, Sasano H, Buscombe J, Lind P, O'Toole D, Oberg K, Palma de Mallorca Consensus Conference Participants ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology. 2010;91:326–332. - PubMed
    1. Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, Mayer C, Aminossadati B, Pape U-F, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663. - PubMed

Publication types

LinkOut - more resources